After literal decades of intense work on developing a vaccine for heroin, chemist Kim Janda of the Scripps Research Institute has finally come exceptionally close. Numerous clinical trials of the vaccine on rats have proven that regardless of how much heroin they are injected with, the vaccine completely counteracts all symptoms of relapse and addiction. While studies have not yet been held on human subjects, the results thus far are exceedingly promising. In fact, the eventual release of this vaccine into society could affect the nation as a whole – ultimately saving quadrillions of dollars on healthcare costs. Interestingly enough, however, this is where the issue lies.
Chemist Discovers the Cure for Heroin Addiction
Pharmaceutical companies will never willingly invest in a vaccine that could potentially eliminate heroin addiction throughout the United States. Drug addiction is by far the most profitable enterprise for the American pharmaceutical corporation, bringing in billions of dollars annually. Not only do drugs like Suboxone and methadone thrive based on the continuation of widespread cases of chemical dependency, but the co-occurring disorders diagnosed by high-paid psychiatrists working for rehab centers across the country would not be nearly as lucrative if the rates of addiction began to be compromised. While it is true that many addicts and alcoholics suffer from dual diagnosis disorders such as major depression or bipolar disorder, the amount of those afflicted with mental disorders as well as substance dependency reigns in at less than half of overall cases of addiction. This may be shocking to those who have been refilling prescriptions for Lexapro and Neurontin for years after being vaguely diagnosed as anxious and depressed while completing a 30-day inpatient stint.
Pharmaceutical Companies Are Not Down With Heroin Vaccine Funding
Janda has received harshly limited funding for continued research, despite the fact that further development of this vaccine could prove essential for the renewed success of society by means of decreased future health care costs. For if heroin addiction rates began to dwindle and what has recently become widely known as an ‘epidemic’ starts to stabilize, pharmaceutical companies will have less vulnerability and desperation to prey upon. The business of addiction recovery and relapse is an absurdly profitable one – from detox centers implementing maintenance drugs that may pose the risk of addiction themselves, to inpatient facilities that hand out psychological diagnoses like candy, the industry is rich in opportunities to benefit off of dead ends and despondency. Media attention regarding such innovations lacks for similar reasons. If the general public becomes aware that there may be a vaccine for heroin addiction, the entire longstanding foundation of recovery and pharmaceutical involvement itself will be compromised.
Put that in your pipe and smoke it.